Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Fürstenau, M."" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł :
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Autorzy :
Cramer P; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Tresckow JV; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Robrecht S; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Bahlo J; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Fürstenau M; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Langerbeins P; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Pflug N; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Al-Sawaf O; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Heinz WJ; University of Würzburg, Medical Center, Medical Clinic II, Würzburg, Germany.
Vehling-Kaiser U; Tagesklinik Landshut, Landshut, Germany.
Dürig J; University Hospital Essen, Department for Hematology, West German Cancer Center, Essen, Germany.
Tausch E; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
Hensel M; Mannheimer Onkologie Praxis, Mannheim, Germany.
Sasse S; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Fink AM; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Fischer K; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Kreuzer KA; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Böttcher S; Department III of Internal Medicine, Rostock University Medical Center, Rostock, Germany.
Ritgen M; Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Kneba M; Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Wendtner CM; Department of Hematology, Oncology, Immunology, Klinikum Schwabing, Munich, Germany.
Stilgenbauer S; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
Eichhorst B; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Hallek M; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Feb 01; Vol. 106 (2), pp. 543-554. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Adenine/analogs & derivatives ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride ; Humans ; Piperidines ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.
Autorzy :
Fürstenau M; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne.
Hallek M; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne.; Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany.
Eichhorst B; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2019 Nov; Vol. 104 (11), pp. 2144-2154. Date of Electronic Publication: 2019 Oct 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Algorithms ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Clinical Trials as Topic ; Combined Modality Therapy ; Disease Management ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Molecular Targeted Therapy ; Treatment Outcome
Czasopismo naukowe
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies